Zhejiang Wecome Pharmaceutical Hits Day High with 15.81% Surge

Zhejiang Wecome Pharmaceutical Co., Ltd. has experienced a significant surge in its stock price, gaining 15.81% on June 9, 2026. The stock reached an intraday high of CNY 31.58, marking a notable performance against the backdrop of the China Shanghai Composite, which only rose by 1.28% on the same day. Over the past week, Zhejiang Wecome has shown a robust increase of 5.55%, contrasting with a decline of 1.6% in the broader market. Year-to-date, the company has achieved a performance of 23.76%, significantly outperforming the China Shanghai Composite's 1.04%. Despite these short-term gains, the company faces challenges in terms of long-term growth, with net sales declining at an annual rate of 16.99% over the last five years. Additionally, the company has a low return on capital employed (ROCE) of 5.02% and a return on equity (ROE) of -22.55%, indicating profitability concerns. Zhejiang Wecome remains a small-cap player in the pharmaceuticals and biotechnology sector, with a market capitalization of CNY 1,086 million.